143838-10-2

Basic information

• Product Name: (2S,3S,4S,5S)-2,5-bis<<(benzyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane
• Synonyms: (2S,3S,4S,5S)-2,5-bis<<(benzyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane
• CAS NO: 143838-10-2
• Molecular Weight: 568.67
• Mol File: 143838-10-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (2S,3S,4S,5S)-2,5-bis<<(benzyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S,4S,5S)-2,5-bis<<(benzyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane(143838-10-2)
• EPA Substance Registry System: (2S,3S,4S,5S)-2,5-bis<<(benzyloxy)carbonyl>amino>-3,4-dihydroxy-1,6-diphenylhexane(143838-10-2)

Safety Data

• Hazardous Substances Data: 143838-10-2(Hazardous Substances Data)

Upstream product

• 6372-14-1 N-((benzyloxy)carbonyl)-L-phenylalaninol 
• 59830-60-3 benzyl (1S)-(1-formyl-2-phenylethyl)carbamate 

Downstream Products

• 134878-06-1 (2S,3S,4S,5S)-2,5-diamino-1,6-diphenyl-3,4-hexanediol 

Relevant articles and documents

Method for synthesis of C2-symmetric diamino diol mediated by titanium complexes

A method for synthesis of C2-symmetric diamino diol mediated by titanium complexes is provided. A substituted-L-phenylalaninal undergoes pinacol coupling to yield the corresponding C2-symmetric (1S,2R,3R,4S)-1,4-diamino 2,3-diol in the presence of Cp2TiCl2/ZnCl2 and zinc metal, mediated in good yield and highly selective. This titanium-catalyzed reaction yields diaminodiol, offering a convenient alternative method to the synthesis of C2-symmetric peptidic protease inhibitors. Consequently, the method allows to synthesize TL-3 via titanium complex in moderate yield.

Pharmaceutical composition

A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.